SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron

The emergence of SARS-CoV-2 Omicron and other variants of concern (VOCs) has brought huge challenges to control the COVID-19 pandemic, calling for urgent development of effective vaccines and therapeutic drugs. In this study, we focused on characterizing the impacts of divergent VOCs on the antivira...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Yuanmei Zhu, Xiaojing Dong, Nian Liu, Tong Wu, Huihui Chong, Xiaobo Lei, Lili Ren, Jianwei Wang, Yuxian He
Materialtyp: Artikel
Språk:English
Publicerad: Taylor & Francis Group 2022-12-01
Serie:Emerging Microbes and Infections
Ämnen:
SARS-CoV-2
variants of concern
Omicron
fusion inhibitor
lipopeptide
Länkar:https://www.tandfonline.com/doi/10.1080/22221751.2022.2098060

Internet

https://www.tandfonline.com/doi/10.1080/22221751.2022.2098060

Liknande verk